Accurate Prediction of Conversion to Alzheimer’s Disease using Imaging, Genetic, and Neuropsychological Biomarkers
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
A variety of imaging, neuropsychological, and genetic biomarkers have been suggested as potential biomarkers for the identification of mild cognitive impairment (MCI) in patients who later develop Alzheimer’s disease (AD). Here, we systematically evaluated the most promising combinations of these biomarkers regarding discrimination between stable and converter MCI and reflection of disease staging. Alzheimer’s Disease Neuroimaging Initiative data of AD ( n = 144), controls ( n = 112), stable ( n = 265) and converter ( n = 177) MCI, for which apolipoprotein E status, neuropsychological evaluation, and structural, glucose, and amyloid imaging were available, were included in this study. Naïve Bayes classifiers were built on AD and controls data for all possible combinations of these biomarkers, with and without stratification by amyloid status. All classifiers were then applied to the MCI cohorts. We obtained an accuracy of 76% for discrimination between converter and stable MCI with glucose positron emission tomography as a single biomarker. This accuracy increased to about 87% when including further imaging modalities and genetic information. We also identified several biomarker combinations as strong predictors of time to conversion. Use of amyloid validated training data resulted in increased sensitivities and decreased specificities for differentiation between stable and converter MCI when amyloid was included as a biomarker but not for other classifier combinations. Our results indicate that fully independent classifiers built only on AD and controls data and combining imaging, genetic, and/or neuropsychological biomarkers can more reliably discriminate between stable and converter MCI than single modality classifiers. Several biomarker combinations are identified as strongly predictive for the time to conversion to AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“1 [55–92] 74.”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“The known limited accuracy of clinical diagnoses may lead to the inclusion of other dementias in the AD groups or of preclinical AD as healthy controls [29, 30].”
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958 · cited 1×
“Whilst most studies have focused on single biomarkers [10–17], multiple studies have also applied machine learning algorithms to compare biomarkers and their combinations with the intent of capturing different aspects of the complex pathophysiology of AD [18–27].”
Mosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E. M., Holthoff, V., Kalbe, E., Sorbi, S., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045385 · Cited by 726 · cited 2×
“Whilst most studies have focused on single biomarkers [10–17], multiple studies have also applied machine learning algorithms to compare biomarkers and their combinations with the intent of capturing different aspects of the complex pathophysiology of AD [18–27].”
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707 · cited 1×
“1 [55–92] 74.”
Cited by
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 315
Lombardi, G., Crescioli, G., Cavedo, E., Lucenteforte, E., Casazza, G., Bellatorre, A.-G., Lista, C., Costantino, G., Frisoni, G., Virgili, G., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009628.pub2 · Cited by 214
Ansart, M., Epelbaum, S., Bassignana, G., Bône, A., Bottani, S., Cattai, T., Couronné, R., Faouzi, J., Koval, I., Louis, M., et al. (2021) · Medical Image Analysis · doi:10.1016/j.media.2020.101848 · Cited by 116
Artificial intelligence and neuropsychological measures: the case of Alzheimer's disease
Battista, P., Salvatore, C., Berlingeri, M., Cerasa, A., & Castiglioni, I. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.04.026 · Cited by 98
Thung, K.-H., Yap, P.-T., Adeli, E., Lee, S.-W., & Shen, D. (2018) · Medical Image Analysis · doi:10.1016/j.media.2018.01.002 · Cited by 89
Salvatore, C., Cerasa, A., & Castiglioni, I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00135 · Cited by 78
Tsolaki, A. C., Kosmidou, V., Kompatsiaris, I. (., Papadaniil, C., Hadjileontiadis, L., Adam, A., & Tsolaki, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.025 · Cited by 70
“(Dukart et al., 2015) suggest that a combination of imaging, genetic and neuropsychological biomarkers can discriminate”
Radiogenomics for Precision Medicine With a Big Data Analytics Perspective
Panayides, A. S., Pattichis, M. S., Leandrou, S., Pitris, C., Constantinidou, A., & Pattichis, C. S. (2019) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2018.2879381 · Cited by 66
Smailagic, N., Lafortune, L., Kelly, S., Hyde, C., & Brayne, C. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171125 · Cited by 61
Kauppi, K., Fan, C. C., McEvoy, L. K., Holland, D., Tan, C. H., Chen, C.-H., Andreassen, O. A., Desikan, R. S., Dale, A. M., & Initiative, T. A. D. N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00260 · Cited by 60
Predictive classification of Alzheimer’s disease using brain imaging and genetic data
Sheng, J., Xin, Y., Zhang, Q., Wang, L., Yang, Z., & Yin, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-06444-9 · Cited by 50
“Dukart et al. 14 obtained an accuracy of 76% via Naive Bayes to identify converter and stable MCI with glucose positron emission tomography as a single biomarker.”
Method
Metadata
- Authors
- Dukart, J., Sambataro, F., Bertolino, A., & Initiative, F. T. A. D. N.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2015-11-23
- Volume
- 49
- Issue
- 4
- Pages
- 1143-1159
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2173926283
- Cited by
- 68
- References
- 22
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.